CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash Flows from Operating Activities:
Net income	$ 86,153	$ 176,156
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	19,705	21,763
Non-cash compensation	15,990	17,860
Amortization and impairment of operating lease right of use assets	34,782	30,181
Loss (gain) on disposal of property and equipment	507	(64)
Gain on equity method investments	0	(31,092)
Deferred income taxes	19,031	34,729
Equity in loss (earnings) from equity method investments	442	(3,932)
Amortization of deferred debt issuance costs/debt discount	743	669
Return on equity method investments	3,798	4,268
Investment impairment	3,009	0
Changes in operating assets and liabilities, net of impact of acquisitions:
Patient accounts receivable	(18,266)	(17,638)
Other current assets	(19,929)	(6,219)
Other assets	283	(938)
Accounts payable	5,886	(1,192)
Accrued expenses	(26,790)	(9,363)
Other long-term obligations	243	(1,785)
Operating lease liabilities	(30,864)	(27,372)
Operating lease right of use assets	(2,323)	(2,304)
Net cash provided by operating activities	92,400	183,727
Cash Flows from Investing Activities:
Proceeds from the sale of deferred compensation plan assets	89	126
Proceeds from the sale of property and equipment	66	140
Purchases of property and equipment	(4,338)	(5,187)
Investments in technology assets	(848)	(147)
Investment in equity method investee	(637)	0
Purchase of cost method investment	(15,000)	0
Acquisitions of businesses, net of cash acquired	(71,952)	(264,872)
Net cash used in investing activities	(92,620)	(269,940)
Cash Flows from Financing Activities:
Proceeds from issuance of stock upon exercise of stock options	1,078	1,706
Proceeds from issuance of stock to employee stock purchase plan	2,857	3,022
Shares withheld to pay taxes on non-cash compensation	(7,949)	(16,694)
Noncontrolling interest contributions	2,100	0
Noncontrolling interest distributions	(1,425)	(1,253)
Proceeds from sale of noncontrolling interest	3,941	0
Proceeds from borrowings under term loan	0	290,312
Proceeds from borrowings under revolving line of credit	484,000	500,700
Repayments of borrowings under revolving line of credit	(465,500)	(551,700)
Principal payments of long-term obligations	(10,126)	(5,893)
Debt issuance costs	0	(2,792)
Purchase of company stock	(17,351)	(84,879)
Payment of accrued contingent consideration	(5,714)	0
Provider relief fund advance	0	(1,465)
Net cash (used in) provided by financing activities	(14,089)	131,064
Net (decrease) increase in cash, cash equivalents and restricted cash	(14,309)	44,851
Cash, cash equivalents and restricted cash at beginning of period	45,769	83,357
Cash, cash equivalents and restricted cash at end of period	31,460	128,208
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	9,153	3,479
Cash paid for Infinity ZPIC interest	11,544	0
Cash paid for income taxes, net of refunds received	23,582	25,482
Cash paid for operating lease liabilities	33,187	29,676
Cash paid for finance lease liabilities	1,074	1,509
Supplemental Disclosures of Non-Cash Activity:
Right of use assets obtained in exchange for operating lease liabilities	36,980	34,881
Right of use assets obtained in exchange for finance lease liabilities	1,846	814
Reductions to right of use assets resulting from reductions to operating lease liabilities	3,387	1,183
Reductions to right of use assets resulting from reductions to finance lease liabilities	564	0
Accrued contingent consideration	19,195	0
Noncontrolling interest contribution	$ 8,900	$ 0